Literature DB >> 169835

Cytocidal action of anticancer antigens: evaluation of the sensitivity of cultured animal and human cancer cells.

M Shimoyama.   

Abstract

The cultured cell lines Yoshida ascites sarcoma, L-1210 mouse leukemia, OAT cell line derived from human lung cancer of the oat cell type, and P3HR-1 cell line derived from Burkitt's lymphoma have been used for the cell-killing kinetics study of anticancer agents and evaluation of the sensitivity of cells using the soft agar cloning assay method. It has been found that there are 2 types of actions: 1) Type I (cytocidal and concentration-dependent action). The dose survival curves of Type I agents fit the equation log S=log nminuskD (S, surviving fraction; D, concentration of agents; n and k are constant). The sensitivity of cells can be expressed by mean lethal dose 90% (MLD90=1/k). Four cell lines were compared on this basis, and some problems concerning the chemotherapy of human cancer are discussed. Alkylating agents and anticancer antibiotics belonged to this group.2) Type II (cytostatic and time-dependent action). The dose survival curves fit the Gompertz equation S=exp[(minusbeta/alpha)(1minus e-aD)] (beta, population reduction parameter; alpha, constant). The exposure survival curve is negative exponential, indicating that exposure time rather than concentration is the key fo effective cell killing of Type II agents. Difficulties in expression of sensitivity to Type II agents are discussed. Antimetabolites, Vinca alkaloids, and L-asparaginase belonged to this group. The cell-killing kinetics of anticancer agents and comparison of the sensitivity of cells may provide some indications not only of optimal dosage schedules but also of a new approach in screening systems for truly effective agents for human cancer.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169835     DOI: 10.1159/000397593

Source DB:  PubMed          Journal:  Bibl Haematol        ISSN: 0067-7957


  3 in total

Review 1.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

2.  Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  R Ohno; K Kimura; K Ota; Y Miura; A Hoshino; K Hattori; M Hirano; M Ito; T Maekawa; T Nakamura
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

3.  Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma.

Authors:  Ryuta Saito; Masayuki Kanamori; Yukihiko Sonoda; Yoji Yamashita; Kenichi Nagamatsu; Takaki Murata; Shunji Mugikura; Toshihiro Kumabe; Eva Wembacher-Schröder; Rowena Thomson; Teiji Tominaga
Journal:  Neurooncol Adv       Date:  2020-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.